Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 19:19:19 29/04/2024 BST			5-day change	1st Jan Change
2.31 ^USD	-25.00%		-11.15%	+165.52%

04-24	Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	CI
04-02	Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	CI

Kiromic BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 12, 2022 at 09:19 pm

Kiromic BioPharma, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 8.44 million compared to USD 4.97 million a year ago. Basic loss per share from continuing operations was USD 16.2 compared to USD 20.4 a year ago. Diluted loss per share from continuing operations was USD 16.2 compared to USD 20.4 a year ago.
For the six months, net loss was USD 15.8 million compared to USD 8.83 million a year ago. Basic loss per share from continuing operations was USD 30.6 compared to USD 36.3 a year ago. Diluted loss per share from continuing operations was USD 30.6 compared to USD 36.3 a year ago.

Latest news about Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	04-24	CI
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	04-02	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	04-01	CI
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial	03-19	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	02-14	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	02-11	CI
Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer	01-29	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	01-07	CI
Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial	01-05	CI
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel? for the Treatment of Non-Small Cell Lung Cancer	12-14	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	12-11	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Kiromic Biopharma, Inc. Announces Deltacel?? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center	11-09	CI
Kiromic BioPharma, Inc. and Beverly Hills Cancer Center Enter Clinical Trial Agreement	23/10/23	CI
Kiromic Biopharma, Inc. Appoints Brian Hungerford as Chief Financial Officer	03/10/23	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	26/09/23	CI
Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from S&P TMI Index	18/09/23	CI
Kiromic Biopharma Shares Suspended From Trading on Nasdaq	14/09/23	MT
Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index	13/09/23	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	24/08/23	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	24/07/23	CI
Kiromic Biopharma, Inc. Announces Board Appointments	24/07/23	CI
Wall Street Set to Open Higher Amid Slowing Inflation; Consumer Sentiment Survey Eyed	30/06/23	MT

Chart Kiromic BioPharma, Inc.

Duration

Period

More charts

Company Profile

Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.

Sector

Biotechnology & Medical Research

Calendar

09/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KIROMIC BIOPHARMA, INC.	+165.52%	2.98M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.60%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.58%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs